Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.39 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | PYGM | P11217 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23017509 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL29223633 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL16389053 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL29407009 | 0.93 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL30858806 | 0.93 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL18927292 | 0.93 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL18927294 | 0.93 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3712334 | 0.93 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3481602 | 0.93 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL30701888 | 0.93 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067336-A1 | METHODS FOR TREATING A DISEASE OR DISORDER USING ORAL FORMULATIONS OF CYTIDINE ANALOGS IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | CELGENE CORP (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067336-A1 | METHODS FOR TREATING A DISEASE OR DISORDER USING ORAL FORMULATIONS OF CYTIDINE ANALOGS IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | PDCD1, PDCD5, PDCD10 | PYGB 3474/4885PYGL 3226/4885PYGM 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.